FMS Stock Recent News

Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering  high-volume hemodiafiltration therapy to dialysis patients Introducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategy BAD HOMBURG, Germany , June 4, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today begins the second phase of the company's efforts to introduce high-volume hemodiafiltration (HVHDF) kidney replacement therapy across the United States. The company last week received FDA 510(k) clearance for the updated version of its new, hemodiafiltration-capable 5008X CAREsystem with additional features, a key benchmark enabling the next steps in the company's broader commercialization efforts across the U.S. later this year, followed by a full-

Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient outcomes. Top Abstract recognition for "Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort," presented in the "Dialysis" category.

Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growth In 2024, organic revenue growth1 was 4 percent, and operating income increased by 18 percent on an outlook base2, coming in at the upper end of the company's outlook The company is well positioned for double digit earnings growth in 2025, translating to an 11-12 percent margin BAD HOMBURG, Germany , May 22, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, continuously executed its strategic plan during the 2024 fiscal year. The success of this transformation is strengthening the foundation for sustainable, profitable growth — both now and in the future.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Does Fresenius (FMS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.

OTTAWA, ON / ACCESS Newswire / May 14, 2025 / Focus Graphite Advanced Materials Inc. (TSXV:FMS)(OTCQB:FCSMF)(FSE:FKC) ("Focus" or the "Company"), announced the grant of incentive stock options as compensation to its officers and consultants. Options to purchase up to 963,084 Common Shares of the Company were granted at an exercise price of $0.09 per share.

CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.

BNTGY, SSUMY and FMS made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 9, 2025.